Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.80 |
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | KRAS | P01116 | 3/20 | 0.75 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.74 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.70 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.70 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.70 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.67 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.67 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.67 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.65 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.64 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.64 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gtp SCHEMBL96708 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL19691775 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL18784960 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376139 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL1304258 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL3333959 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL376140 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL5809658 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| Gtp SCHEMBL17367368 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 | |
| SCHEMBL2593095 | 0.99 | TGM2 (0.81) | TGM2NT5EKRASFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958840-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230114472-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2023-04-13 | — | — | US | disclosed |
| EP-3923935-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Denali Therapeutics Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113518618-A | Compounds, compositions and methods | 戴纳立制药公司 | 2021-10-19 | — | — | CN | disclosed |
| US-20210292311-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2020168011-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2020-08-20 | — | — | WO | disclosed |
| EP-2922821-B1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10273234-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | BIOGEN MA INC. (US) | 2019-04-30 | — | — | US | disclosed |
| CN-104169438-B | Asymmetric hairpin target capture oligomers | 简·探针公司 | 2019-02-26 | — | — | CN | disclosed |
| EP-2963114-B1 | METHOD FOR PREDICTING RESPONSIVENESS TO COMPOUND INHIBITING MAPK SIGNAL TRANSDUCTION PATHWAY | DAIICHI SANKYO CO LTD (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-20110207143-A1 | DIAGNOSTIC TEST FOR MUTATIONS IN CODONS 12-13 OF HUMAN K-RAS | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2358905-A1 | DIAGNOSTIC TEST FOR MUTATIONS IN CODONS 12-13 OF HUMAN K-RAS | Abbott Laboratories (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010071821-A1 | DIAGNOSTIC TEST FOR MUTATIONS IN CODONS 12-13 OF HUMAN K-RAS | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | WO | disclosed |
| US-7018824-B2 | Mannosyl transfer with regeneration of GDP-mannose | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050221447-A1 | water soluble transferase enzyme polypeptides, coded by exogenous DNA; glycosylation | THE SCRIPPS RESEARCH INSTITUTE | 2005-10-06 | — | — | US | disclosed |
| US-6919440-B2 | Mannosyl transfer with regeneration of GDP-mannose | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030119090-A1 | Mannosyl transfer with regeneration of GDP-mannose | WONG CHI-HUEY (US) | 2003-06-26 | — | — | US | disclosed |
| US-6485930-B1 | Mannosyl transfer with regeneration of GDP-mannose | THE SCRIPPS RESEARCH INSTITUTE | 2002-11-26 | — | — | US | disclosed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958840-B2 | Compounds, compositions and methods | EIF4EBP1, EIF4B, EIF4E | TGM2 2421/4885NT5E 2559/4885KRAS 585/4885 |
| US-20230114472-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | TGM2 2421/4885NT5E 2559/4885KRAS 585/4885 |
| US-20210292311-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | TGM2 2421/4885NT5E 2559/4885KRAS 585/4885 |
| US-10273234-B2 | Compounds that are S1P modulating agents and/or ATX modulating agents | ENPP2, S1PR1, S1PR2 | TGM2 2684/4885NT5E 1329/4885KRAS 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.